2 results
Approved WMOPending
The primary objective of the study is to evaluate the safety and efficacy of Anecortave Acetate Depot (3, 15 or 30 mg) when administered by AJD for treatment of elevated IOP following intravitreal steroid therapy.
Approved WMORecruiting
With the goal of improving kidney function and without causing an increased number of rejections, is it possible to reduce tacrolimus dosage through the use of the previously-mentioned immunosupressives after month three.